Val Tate

Bio

Over 16 years' commercial experience in startup, private and publicly traded biotechnology companies, holding roles in Business Development and Commercial management. This broad experience, encompassing therapeutics, diagnostics and forensics, informs her top-level, strategic advice to senior management on quality dialogue with all stakeholders, including the City, regulators, partners, the media and employees. A background in medical communications for major international pharmaceutical companies was excellent grounding for her former role as Head of Investor Relations at London-based cancer company Antisoma as a member of the IPO team. Took part in subsequent fundraising rounds. Broadened this experience at NASDAQ and LSE-listed drug delivery company SkyePharma. Now advises clients on the formulation and articulation of company strategy through diverse media including business planning, presentations and websites. Member and former Board Director of the Investor Relations Society. PhD in biochemistry. Widely published in virology, gene structure, cloning and express ion, and molecular genetics.